3.6% Above Target

Wall Street's consensus price target for ACA is $140, -3.6% from its current price of $145.29. The below-market target from 8 analysts suggests limited near-term appreciation.

ACA has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $140 implies -3.6% downside from current levels.

ACA trades at a forward P/E of 33.9598x, representing a moderate valuation. With analysts targeting $140 (-3.6% implied move), the stock appears close to fair value.

The most bullish Wall Street analyst has a price target of $140 for ACA, while the most conservative target is $140. The consensus of $140 represents the median expectation. Our quantitative valuation model projects a bull case target of $190 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

ACA is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month ACA stock forecast based on 8 Wall Street analysts shows a consensus price target of $140, with estimates ranging from $140 (bear case) to $140 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $144, with bear/bull scenarios of $91/$190.

Our quantitative valuation model calculates ACA's fair value at $144 (base case), with a bear case of $91 and bull case of $190. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.

ACA trades at a forward P/E ratio of 34.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 34.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Analysts are cautious on ACA, with 0 Sell ratings and a price target of $140 (-3.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

ACA analyst price targets range from $140 to $140, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $140 consensus represents the middle ground. Our model's $91-$190 range provides an independent fundamental perspective.